Mateon Therapeutics announces results from second interim analysis of CA4P phase 2/3 study
Mateon Therapeutics announced results from its second scheduled interim analysis of the ongoing phase 2/3 FOCUS study evaluating CA4P in combination with bevacizumab (Avastin®) and physician's choice chemotherapy in patients with platinum resistant ovarian cancer. August 16, 2017